Sarepta Therapeutics

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
Endpoints
Duchenne Muscular Dystrophy
ICER
Sarepta Therapeutics
Exondys 51
Flag link:
These 6 biotech stocks are promising takeover targets
These 6 biotech stocks are promising takeover targets
Marketwatch
M&A
Sarepta Therapeutics
Amarin
Intercept Pharmaceuticals
Immunomedics
Alder Biopharmaceuticals
Biogen
Flag link:
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Yahoo/Benzinga
Wave Life Sciences
Sarepta Therapeutics
Novavax
ContraFect
Scynexis
earnings
Abbott Labs
Intuitive Surgical
Brainsway
Hookipa
Turning Point Therapeutics
IPOs
Flag link:
Sarepta to seek speedy approval of third DMD drug
Sarepta to seek speedy approval of third DMD drug
Biopharma Dive
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
casimersen
Flag link:
Gene Therapy Market Heats up as Sarepta Buys Myonexus for $165 Million
Gene Therapy Market Heats up as Sarepta Buys Myonexus for $165 Million
BioSpace
Sarepta Therapeutics
gene therapy
M&A
Myonexus
Flag link:
CRISPR corrects DMD in mice for a year in Sarepta-supported study
CRISPR corrects DMD in mice for a year in Sarepta-supported study
Fierce Biotech
Duke University
Sarepta Therapeutics
CRISPR
gene editing
DMD
Duchenne Muscular Dystrophy
Flag link:
[audio+transcript] 6 Biotech Stocks to Watch Now
[audio+transcript] 6 Biotech Stocks to Watch Now
Motley Fool
Biogen
Bluebird Bio
Global Blood Therapeutics
Aimmune Therapeutics
Vertex Pharmaceuticals
Sarepta Therapeutics
Flag link:
Moment of truth for Sarepta and Myonexus
Moment of truth for Sarepta and Myonexus
EP Vantage
Sarepta Therapeutics
gene therapy
MYO-101
Limb Girdle Muscular Dystrophy
Flag link:
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
Motley Fool
FDA
gene editing
Novartis
Sarepta Therapeutics
CAR-T
Alzheimer's disease
Flag link:
Hunting productivity, drugmakers pitch new 'pillars' of R&D
Hunting productivity, drugmakers pitch new 'pillars' of R&D
Biopharma Dive
R&D
Moderna Therapeutics
Sarepta Therapeutics
Ionis Pharmaceuticals
Flag link:
Six Things to Watch for at the JP Morgan Healthcare Conference
Six Things to Watch for at the JP Morgan Healthcare Conference
BioSpace
Moderna Therapeutics
Sarepta Therapeutics
Biogen
Gilead Sciences
Bluebird Bio
Flag link:
Sarepta inks deal to bolster gene therapy manufacturing
Sarepta inks deal to bolster gene therapy manufacturing
Biopharma Dive
Sarepta Therapeutics
Aldevron
gene therapy
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
Sarepta, AcelRx Look to Infuse Some Cash into Their Pipelines
Sarepta, AcelRx Look to Infuse Some Cash into Their Pipelines
BioSpace
Sarepta Therapeutics
AcelRx
stock offering
Flag link:
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
CP Wire
Myonexus
Sarepta Therapeutics
muscular dystrophy
gene therapy
Flag link:
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
Myonexus
Sarepta Therapeutics
muscular dystrophy
Flag link:
Antisense startup Stoke Therapeutics secures another $90M in series B funding
Antisense startup Stoke Therapeutics secures another $90M in series B funding
Endpoints
Stoke Therapeutics
Sarepta Therapeutics
Flag link:
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Forbes
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
Flag link:
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
Endpoints
Sarepta Therapeutics
FDA
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Flag link:
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:

Pages